| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2015 | 2991 | 1.380 |
Why?
|
| Neoplasms | 21 | 2023 | 3020 | 1.270 |
Why?
|
| Neoplasm Metastasis | 19 | 2016 | 1107 | 1.080 |
Why?
|
| Prostatic Neoplasms | 9 | 2007 | 1767 | 0.690 |
Why?
|
| Radiotherapy | 6 | 2014 | 331 | 0.690 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 504 | 0.660 |
Why?
|
| Antineoplastic Agents | 8 | 2015 | 2410 | 0.500 |
Why?
|
| Knowledge | 1 | 2014 | 29 | 0.480 |
Why?
|
| Neovascularization, Pathologic | 6 | 2004 | 363 | 0.460 |
Why?
|
| Education, Medical | 2 | 2014 | 243 | 0.460 |
Why?
|
| Models, Theoretical | 3 | 2005 | 491 | 0.440 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 105 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2004 | 832 | 0.420 |
Why?
|
| Lymphatic Metastasis | 8 | 2003 | 502 | 0.400 |
Why?
|
| Humans | 72 | 2023 | 88852 | 0.400 |
Why?
|
| Physician-Patient Relations | 4 | 2007 | 625 | 0.390 |
Why?
|
| Radiation, Ionizing | 4 | 2010 | 121 | 0.370 |
Why?
|
| Radiation Oncology | 3 | 1997 | 121 | 0.360 |
Why?
|
| Human Experimentation | 1 | 2010 | 39 | 0.340 |
Why?
|
| Nucleoside-Diphosphate Kinase | 2 | 2000 | 12 | 0.340 |
Why?
|
| Ethics, Research | 1 | 2010 | 52 | 0.340 |
Why?
|
| Monomeric GTP-Binding Proteins | 2 | 2000 | 19 | 0.330 |
Why?
|
| Disease-Free Survival | 12 | 2011 | 1213 | 0.330 |
Why?
|
| Patient Advocacy | 3 | 2015 | 52 | 0.320 |
Why?
|
| MicroRNAs | 4 | 2015 | 550 | 0.320 |
Why?
|
| Physician's Role | 4 | 2005 | 177 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2005 | 485 | 0.300 |
Why?
|
| Genetic Therapy | 9 | 2008 | 369 | 0.290 |
Why?
|
| Models, Economic | 1 | 2007 | 62 | 0.290 |
Why?
|
| Hematopoiesis | 1 | 2008 | 165 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2005 | 1354 | 0.280 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 161 | 0.270 |
Why?
|
| Decision Making | 3 | 2007 | 664 | 0.270 |
Why?
|
| Liver Neoplasms | 3 | 2018 | 754 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2008 | 699 | 0.270 |
Why?
|
| Prostatectomy | 3 | 2007 | 476 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 299 | 0.260 |
Why?
|
| Prognosis | 11 | 2005 | 3757 | 0.260 |
Why?
|
| Androgen Antagonists | 2 | 2005 | 154 | 0.260 |
Why?
|
| Attitude of Health Personnel | 2 | 2005 | 643 | 0.260 |
Why?
|
| Transcription Factors | 6 | 2004 | 1650 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2003 | 156 | 0.250 |
Why?
|
| Ethics, Medical | 3 | 2000 | 307 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 358 | 0.240 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 980 | 0.240 |
Why?
|
| Attitude to Health | 1 | 2005 | 222 | 0.240 |
Why?
|
| Nitriles | 1 | 2004 | 160 | 0.220 |
Why?
|
| Triazoles | 1 | 2004 | 102 | 0.220 |
Why?
|
| Biomedical Research | 3 | 2014 | 397 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 96 | 0.220 |
Why?
|
| History, 20th Century | 3 | 2010 | 310 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2003 | 71 | 0.210 |
Why?
|
| Managed Care Programs | 2 | 2000 | 42 | 0.210 |
Why?
|
| Brachytherapy | 1 | 2003 | 121 | 0.200 |
Why?
|
| Disease Progression | 8 | 2012 | 1483 | 0.190 |
Why?
|
| Melanoma | 2 | 2013 | 466 | 0.190 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2000 | 67 | 0.190 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 220 | 0.190 |
Why?
|
| Lymph Nodes | 4 | 2000 | 548 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2003 | 1532 | 0.190 |
Why?
|
| Aged | 16 | 2018 | 19019 | 0.190 |
Why?
|
| Medical Oncology | 2 | 2014 | 379 | 0.180 |
Why?
|
| Female | 31 | 2018 | 45899 | 0.180 |
Why?
|
| Carcinoma | 1 | 2003 | 442 | 0.180 |
Why?
|
| Survival Analysis | 6 | 2013 | 1533 | 0.170 |
Why?
|
| Combined Modality Therapy | 9 | 2005 | 1708 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 1146 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 578 | 0.160 |
Why?
|
| Cadherins | 1 | 2000 | 163 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2013 | 280 | 0.160 |
Why?
|
| Middle Aged | 16 | 2018 | 25787 | 0.160 |
Why?
|
| Mammography | 2 | 2000 | 469 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2005 | 295 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 134 | 0.150 |
Why?
|
| History, 21st Century | 2 | 2009 | 180 | 0.140 |
Why?
|
| Immediate-Early Proteins | 4 | 2004 | 165 | 0.140 |
Why?
|
| Mastectomy | 2 | 2004 | 245 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2000 | 383 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 1998 | 332 | 0.140 |
Why?
|
| Prescription Fees | 1 | 2015 | 10 | 0.130 |
Why?
|
| Consumer Advocacy | 1 | 1995 | 10 | 0.130 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 2347 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 1996 | 118 | 0.130 |
Why?
|
| Microcirculation | 3 | 2000 | 104 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 1996 | 83 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 6758 | 0.120 |
Why?
|
| United States | 7 | 2015 | 6931 | 0.120 |
Why?
|
| Drug Costs | 1 | 2015 | 63 | 0.120 |
Why?
|
| Erectile Dysfunction | 2 | 2007 | 75 | 0.120 |
Why?
|
| Neoplasm Staging | 5 | 2004 | 1989 | 0.120 |
Why?
|
| Patients | 1 | 1995 | 102 | 0.120 |
Why?
|
| Medical Laboratory Science | 1 | 1994 | 7 | 0.120 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2008 | 25 | 0.120 |
Why?
|
| Clinical Medicine | 1 | 1994 | 34 | 0.120 |
Why?
|
| Life Expectancy | 1 | 1994 | 89 | 0.110 |
Why?
|
| Aging | 1 | 1998 | 713 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 1994 | 115 | 0.110 |
Why?
|
| Patient Participation | 1 | 2015 | 224 | 0.110 |
Why?
|
| Urinary Incontinence | 2 | 2007 | 213 | 0.110 |
Why?
|
| Male | 13 | 2018 | 42135 | 0.110 |
Why?
|
| Health Care Reform | 1 | 1994 | 85 | 0.110 |
Why?
|
| History, 19th Century | 2 | 2009 | 56 | 0.110 |
Why?
|
| Adult | 12 | 2018 | 26439 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2004 | 299 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2013 | 8178 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 478 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2005 | 430 | 0.090 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 397 | 0.090 |
Why?
|
| Age Factors | 3 | 2007 | 1862 | 0.090 |
Why?
|
| Animals | 15 | 2016 | 27272 | 0.090 |
Why?
|
| Informed Consent | 2 | 2010 | 274 | 0.090 |
Why?
|
| Philosophy, Medical | 2 | 2005 | 17 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2000 | 3649 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 1998 | 986 | 0.090 |
Why?
|
| Ohio | 1 | 2010 | 39 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2004 | 168 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1991 | 181 | 0.090 |
Why?
|
| NM23 Nucleoside Diphosphate Kinases | 2 | 2000 | 6 | 0.080 |
Why?
|
| Biological Evolution | 1 | 1997 | 963 | 0.080 |
Why?
|
| Research Subjects | 1 | 2010 | 73 | 0.080 |
Why?
|
| Lung | 2 | 2012 | 1257 | 0.080 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Universities | 1 | 2010 | 146 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2004 | 901 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2549 | 0.080 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 2344 | 0.080 |
Why?
|
| Military Personnel | 1 | 2010 | 91 | 0.080 |
Why?
|
| Survival Rate | 3 | 2012 | 1881 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 96 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1194 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2008 | 104 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 84 | 0.080 |
Why?
|
| Philosophy | 1 | 2007 | 9 | 0.080 |
Why?
|
| Urethral Stricture | 1 | 2007 | 14 | 0.070 |
Why?
|
| Rectal Diseases | 1 | 2007 | 24 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1993 | 598 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2007 | 37 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2004 | 1241 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1997 | 66 | 0.070 |
Why?
|
| Mutation | 1 | 2018 | 4121 | 0.070 |
Why?
|
| Time Factors | 4 | 2005 | 5313 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2439 | 0.070 |
Why?
|
| Fund Raising | 1 | 2005 | 2 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2006 | 32 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2003 | 1713 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2002 | 1974 | 0.070 |
Why?
|
| Dermatology | 1 | 2006 | 40 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 1796 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1428 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2005 | 71 | 0.060 |
Why?
|
| Heterografts | 2 | 2015 | 102 | 0.060 |
Why?
|
| Sample Size | 1 | 2005 | 128 | 0.060 |
Why?
|
| Mastectomy, Radical | 2 | 1995 | 10 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2003 | 894 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2007 | 461 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 116 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 225 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 849 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2004 | 298 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2550 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 24 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2005 | 447 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 575 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 130 | 0.050 |
Why?
|
| Mice | 9 | 2015 | 11722 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 205 | 0.050 |
Why?
|
| Early Growth Response Protein 1 | 4 | 2004 | 56 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 858 | 0.050 |
Why?
|
| Lymphedema | 1 | 2003 | 77 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 291 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 2013 | 0.050 |
Why?
|
| Risk | 1 | 2003 | 657 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 695 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 178 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2005 | 2286 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1057 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1309 | 0.040 |
Why?
|
| Cisplatin | 1 | 2002 | 617 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 94 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2002 | 814 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2001 | 160 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 967 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 81 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1399 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 1715 | 0.040 |
Why?
|
| Plasminogen | 1 | 1998 | 45 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2004 | 446 | 0.040 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2000 | 158 | 0.040 |
Why?
|
| Research | 2 | 2003 | 252 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1155 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 78 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1835 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2011 | 470 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1997 | 202 | 0.040 |
Why?
|
| Axilla | 1 | 1997 | 104 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 540 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 1996 | 45 | 0.040 |
Why?
|
| Insurance, Health | 1 | 1998 | 159 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1996 | 81 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1998 | 461 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 155 | 0.030 |
Why?
|
| Researcher-Subject Relations | 1 | 1996 | 4 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 420 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1996 | 89 | 0.030 |
Why?
|
| Social Responsibility | 1 | 1996 | 57 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 1113 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2001 | 664 | 0.030 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 85 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 62 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 1996 | 179 | 0.030 |
Why?
|
| DNA Repair | 1 | 1997 | 361 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1997 | 597 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 1995 | 89 | 0.030 |
Why?
|
| Algorithms | 1 | 2003 | 1870 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 195 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1995 | 251 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 261 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 1996 | 848 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 1995 | 269 | 0.030 |
Why?
|
| Research Design | 2 | 2003 | 597 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 308 | 0.030 |
Why?
|
| Social Values | 1 | 1994 | 44 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 582 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 590 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 1994 | 71 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 386 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1994 | 101 | 0.030 |
Why?
|
| Health Care Costs | 1 | 1995 | 235 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 1995 | 207 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 305 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 595 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 285 | 0.030 |
Why?
|
| Adenoviridae | 2 | 2004 | 349 | 0.030 |
Why?
|
| Social Change | 1 | 1991 | 8 | 0.020 |
Why?
|
| England | 1 | 1991 | 38 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 80 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 272 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 371 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 153 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 263 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 956 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 408 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 1095 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 33 | 0.020 |
Why?
|
| Esophageal Neoplasms | 2 | 2002 | 332 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 90 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1993 | 531 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1991 | 1713 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 4039 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 463 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1991 | 433 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1265 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 8963 | 0.020 |
Why?
|
| Necrosis | 2 | 1996 | 209 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2008 | 455 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2750 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2004 | 47 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 97 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2004 | 70 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1996 | 565 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 233 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 975 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 25 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 353 | 0.010 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2003 | 34 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 478 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2000 | 3202 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 392 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 727 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 136 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2000 | 46 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 615 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 89 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 201 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 778 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 123 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 631 | 0.010 |
Why?
|
| Angiostatins | 1 | 1998 | 15 | 0.010 |
Why?
|
| Collagen | 1 | 2000 | 293 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 801 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 433 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 573 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2855 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 783 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1753 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 1938 | 0.010 |
Why?
|
| Mastadenovirus | 1 | 1995 | 4 | 0.010 |
Why?
|
| Liposomes | 1 | 1995 | 93 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2000 | 2879 | 0.010 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1995 | 109 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 1995 | 173 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1995 | 370 | 0.010 |
Why?
|
| Thrombosis | 1 | 1996 | 302 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3370 | 0.010 |
Why?
|